drugset / Trial / NCT04173455
Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
Phase 1
Unknown
46 enrolled
First Affiliated Hospital of Zhejiang University
Hangzhou HeZheng Pharmaceutical Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to establish the safety, tolerability, pharmacokinetics and RP2D (Recommended Phase II Dose) of orally administered HZ-A-018 in patients with B cell lymphoma who have at least failed or relapsed after first-line treatment.
Timeline
- Start
- 2019-10-28
- Primary completion
- 2021-09
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HZ-A-018 | Unknown | — | Oral |